medigraphic.com
ISSN 1527-3172 (Electronic)

2010, Number 1

<< Back Next >>

MEDICC Review 2010; 12 (1)

Hormone receptors and other prognostic factors in breast cancer in Cuba

Álvarez GRI, Escobar PX, Camacho RR, Orozco LM, Franco OS, Llanes FL, Guerra YM, Rodríguez PC

Language: English
References: 52
Page: 36-40
PDF size: 119.09 Kb.


ABSTRACT

Clinical management of breast cancer, making a prognosis and deciding on treatment, currently depend on defining prognostic factors, especially hormone receptors (HR). In addition to confirming the heterogeneity of the disease, these biological parameters are indispensable tools for designing personalized treatment. In this study, 1509 tumors from Cuban women diagnosed with breast cancer were examined. Hormone receptor (HR) expression was determined and correlated with a group of prognostic factors, such as age, tumor size, histological type, nuclear grade, histological grade, number of metastatic axillary lymph nodes, and clinical stage. Estrogen receptor (ER) expression was associated with low nuclear grade and histological grade, and with smaller tumor size (p ‹ 0.05). Analysis of age at the time of diagnosis showed that ER expression was greater in patients in the group aged › 50 years (p ‹ 0.05). In general, ER expression was greater in patients in earlier clinical stages (p ‹ 0.05). With regard to HR expression, 53% of tumors in this sample were ER+ and 49% were PR+. In 38% of cases, both receptors were positive and in 28% both receptors proved negative. The ER+/PR− combination was observed in 23% of cases while only 11% exhibited the ER−/PR+ combination. These findings indicate that approximately 72% of the tumors studied expressed some level of hormone dependency. This is the first report of HR expression in Cuba using immunohistochemical techniques and a representative sample of breast tumors diagnosed in different provinces around the country.


REFERENCES

  1. Reporte del Registro Nacional de Cáncer y del Anuario Estadístico. Cuba 2006.

  2. Rizzi D.A.. Medical prognosis- some fundamentals. Theor Med 1993; 14: 365–375.

  3. Stockler M., Boyd N., Tannock I. Guide to studies of diagnostic test, prognostic factors, and treatments,in Tannock I, Hill R (eds.): The basic science of oncology, 3d ed Toronto, McGraw-Hill 1998; 446–492.

  4. Kummel S., Rezai M., Kimmig R., Schmid P. Dose-dense chemotherapy for primary breast cancer. Curr Opin Obstet Gynecol 2007; 19: 75–81.

  5. Pascual M.R., Macias, A., Moreno, L., et al. Determinación de receptores hormonales de tumores mamarios humanos. Rev. Cub. Obstet. Ginecol 1981; 7:1.

  6. Lage A., Pascual, M.R.,et al. Factors associated with prognosis in human breast cancer: predictors for evolution and relapse. Neoplasm 1983; 30: 345.

  7. Macias A., Pascual, M.R., Pérez, R., et al. Factors associated with prognosis in human breast cancer: progesterone receptors and clinical factors. Neoplasm 1983; 30: 232.

  8. Pascual M.R., Rodríguez, M., Zayas, A., et al. Factors associated with prognosis in human breast cancer.II. Multivariate stratification analysis. Neoplasm 1983; 30: 485.

  9. Pascual M.R., Rodríguez, M., Zayas, A., et al. Factors associated with prognosis in human breast cancer.III. Estradiol receptor and short term relapse. Neoplasm 1983; 30: 589.

  10. Pascual, M.R., Macias, A., Lage, A., et al. Factors associated with prognosis in human breast cancer. V. The simultaneous use of estrogen and progesterone receptor measurements for prediction of short-term relapse. Neoplasm 1984; 32: 247.

  11. Sobin L.H., Wittekind C.H. TNM Classification of Malignant Tumours, 5ta ed: A John Wiley and Sons INC, Publication 1997; 123–130.

  12. Llanes, L., Álvarez, R.I., Arango, M.C., et al. Relationship of IL-10 and tumoral markers in breast cancer patients. The Breast 2006; 15: 482–489.

  13. Bailey, J.A. Concise dictionary of medical-legal terms. New York, The Parthanon Publishing Group 1998.

  14. Willems A., Gauger K., Henrichs C. Antibody therapy for breast cancer. Anticancer Res 2005; 25: 1483–1489.

  15. Joensuu H., Kellokumpu Lehtinen P. I., Bono, P., et al . Adjuvant docetaxel or vinorelbine with or without tratuzumab for breast cancer. N. Engl. J. Med 2006; 354: 809–820.

  16. Kurebayashi, J. Current clinical trials of endocrine therapy for breast cancer. Breast Cancer 2007; 14: 200–214.

  17. International Union Against Cancer. Prognostic Factors in Cancer, 2d ed, Gospodarowicz M.K., Henson D.E., Hutter R.V. P., O’Sullivan B., Sobin L.H., Wittekind Ch 2001.

  18. Beatson, G.W. On the treatment of inoperable cases of carcinoma of the mamma: Suggestions for a new method of treatment with illustrative cases. Lancet 1896; 2: 104–107.

  19. Budzar, A., Valero V., Theriault R.L., et al. Pathological complete response to chemotherapy in related with hormonal receptor status. Breast Cancer Res Treat 2003; 82: abstract; 302.

  20. Mouridsen H., Gershanovich M., Sun Y., et al. Superior efficacy of Letrozole (Femara) versus Tamoxifen as first-line therapy for postmenopausal women with advanced breast cancer: Results of Phase III Study of the International Letrozole Breast Cancer Group. J Clin Oncol 2001; 19: 2596–2606.

  21. Mass H., Engle B., Trams G. Steriod hormone receptors in human breast cancer and the clinical significance. J Steriod Biochem 1995; 6: 743–749.

  22. Knight W.A., Livingston R.B., Gregoty B.H., et al. Estrogen receptor as a independent prognostic factor for early recurrence in breast cancer. Cancer Res 1977; 37: 4669–4771.

  23. McCarty, K.S. Jr and McCarty, K.S. Sr. Steroid hormone receptors in the regulation of differentiation. Am J Pathol 1978; 86: 705–744.

  24. Contesso G., Delarue J.C., Mouriesse H., et al. Anatomopathologie du cancer du sein et recepteurs hormnaux. Pathol Biol 1983; 31: 747–734.

  25. Elston C.W., Blamey R.W., Johnson J., et al. The relationship of oestradiol receptors (RE) and histological tumours differentiation with prognosis in human primary breast carcinoma in Moridsen, Palshof, (eds): Breast Cancer: Experimental and clinical aspects. Oxford, Pergamon 1980;59–62.

  26. Veronesi U., Galimberti V., Zurrida S., et al. Prognostic significance of number and level of axillary nodal metástasis in Breast cáncer. Breast 1993; 2: 224–228.

  27. Jatoi I.,Hilsenbeck S.G., Clark G.M., et al. Significance of axillary lymph node metastasis in primary breast cancer. J Clin Oncol 1999; 17: 2334–2340.

  28. Wilkinson N.W., Shahryarinejad, A., Winston, J.S., et al (2003) Concordance with breast cancer pathology reporting practice guidelines. J. Am. Coll. Surg 2003; 193: 38–43.

  29. Rosen P.P. Rosen’s Breast Pathology. Philadelphia: Lippincott-Raven 1997.

  30. White J., Morrow, M., Moughan, J., et al. Compliance with breast conservation standards for patients with early stage breast carcinoma. Cancer 2003; 97: 893-904.

  31. Thorpe S. Estrogen and progesterone receptor determinations in breast cancer. Technology, biology and clinical significance. Acta Oncol 1998; 27: 1–19.

  32. Cheung K., Howell A., Robertson J. Preoperative endocrine therapy for breast cancer. Endocr- Relate Cancer 2000; 7: 131–141.

  33. Joslyn S.A. Hormone receptors in breast cancer: racial differences in distribution and survival. Breast Cancer Res Treat 2002; 73: 45–59.

  34. Chu K.C., Anderson W.F., Fritz a., et al. Frequency distributions of breast cancer characteristics classified by estrogen receptors and progesterone receptor status for eight racial/ethnic groups. Cancer 2001; 92: 37–45.

  35. Lertsanguansinchai P., Chottetanaprasith T., Chatamra K., et al: Estrogen and progesterone receptors status in Thai female breast cancer patients: an analysis of 399 cases at King Chulalongkorn Memorial Hospital. J med Assoc Thai 2002; 85, Suppl 1: s193–202.

  36. Chow L.W., Ho P. Hormonal receptor determination of 1052 Chinese breast cancers. J Surg Oncol 2000; 75: 172–175.

  37. Abadjian G., Antoun R. Breast carcinoma an evaluation of hormone receptors and pS2,erb- B2, P-glycoprotein and Ki-67 markers. J Med Liban 1996; 44: 10–15.

  38. al-Alwan N.A., al-Kubaisy W., al-Rawaq K. Assessment of response to tamoxifen among Iraqi patients with advanced breast cancers. East Mediterr Health J 2000; 6: 475–482.

  39. Samir S. Amr, Abdul Rahman M. Sa`di., Fazal Ilahi., et al. Spectrum of breast diseases in Saudi Arab females: A 26 year pathological survey at Dhaaran Health Center. Ann Med Saudi 1995; 15:125–132.

  40. Ikpatt O.F., Ndoma-Egba R.: oestrogen and progesterone receptors in Nigerian breast cancer: relationship to tumor histopathology and survival of patients. Cent Afr J Med 2003; 49: 122–126.

  41. Maynard P.V., Davis C.J., Blamey R.W., et al. Relationship between estrogen receptor content and histological grade in human primary breast tumors. Br J Cancer 1978; 38: 745–748.

  42. Bezwoda W.R., Esser J.D., Dansey R., et al. The value of estrogen and progesterone receptor determinations in advanced breast cancer. Estrogen receptor level but not progesterone receptor level correlates with response to tamoxifen. Cancer 1991; 68: 867–872.

  43. Early Breast Cancer Trialists Collaborative Group. Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy: 133 randomised trials involving 31 recurrences and 24 000 deaths among 75 000 women. Lancet 1992; 339: 75–81.

  44. Baum M., Buzdar A.U., Cuzicck J., et al. Anastrozole alone or in combination with tamoxifen versus tamoxifene alone for adjuvant treatment of postmenopausal women with early breast cancer: First results of the ATAC randomizaed trial. Lancet 2002; 359: 2131–2139.

  45. Baum M., Buzdar A. The current status of aromatase inhibitors in the management of Breast cancer. Sur Clin North Am 2003; 83: 973–994.

  46. Bardou J.V., Arpino G., Elledge R.M, et al. Progesterone receptor status significantly improves outcome prediction over estrogen receptor status alone for adjuvant endocrine therapy in two large breast cancer databases. J. Clin Oncol 2003; 21: 1973–1979.

  47. Cui X., Zhang P., Deng W., et al. Insuline like growth factor-1 inhibits progesterone receptor expression in breast cancer cells via the phosphatidylinositol 3 kinase/AKT/mammalian target of rapemycin pathway: Progesterone receptor as a potencial indicator of growth factor activity in breast cancer. Mol. Endocrinol 2003; 17: 575–588.

  48. Cui X., Schiff R., Arpino G., Osborne C.K., Lee A. V. Biology of progesterone receptor loss in Breast Cancer snd its implications for endocrine therapy. J. Clin Oncol 2005; 23:7721–7735.

  49. Konecny G., Pauletty G.,Pegram M., et al. Quantitative association between HER2/neu and steroid hormone receptors in hormone receptor positive primary breast cancer. J natl Cancer. Inst 2003; 95: 142–153.

  50. Pozone F., Montemurro F., Maggiorotto C., et al. Clinical outcome of adjuvant endocrine treatment according to RP and HER2 status in early breast cancer. Ann Oncol 2006; 17: 1631–1636.

  51. Stierer M., Rosen H., Weber R., et al. Inmunohistochemical and biochemical measurement of estrogen and progesterone receptors in primary breast cancer. Correlation of histopathology and prognostic factors. Ann Surg 1993; 218: 13–21.

  52. Early Breast Cáncer Trialist Collaborative Group (EBCTCG), Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15 year survival: an overview of the randomised trials. Lancet 2005; 365: 1687–1717.




2020     |     www.medigraphic.com